Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-phospho-D-arabinohydroxamic acid
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
5-phospho-D-arabinohydroxamic acid is a synthetic small molecule belonging to the class of pentose phosphates. It is structurally similar to reaction intermediates in sugar metabolism and acts as a potent inhibitor of phosphoglucose isomerase by mimicking the cis-enediol(ate) intermediate but with a nitrogen atom replacing C1. This compound has been used experimentally to study enzyme mechanisms and inhibition but has no approved medical indications or clinical use[1][8].
- Other names
- 5-phospho-D-arabinohydroxamic acid(2R,3R,4S)-2,3,4-Trihydroxy-5-(hydroxyamino)-5-oxopentyl dihydrogen phosphate
02
Targets
PMI (Plasmepsin I)GPI (Glucose-6-phosphate isomerase)
Beyond the preview
Go deeper on 5-phospho-D-arabinohydroxamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-phospho-D-arabinohydroxamic acid.